Filgotinib: Positive results

Gilead and Galapagos announced the successful completion of the phase 2 EQUATOR study of filgotinib, in patients with moderate to severe psoriatic arthritis. Concurrently, they announced the progression of SELECTION study  of filgotinib in patients with ulcerative colitis, to phase 3.

Read the official press release here.